News | April 11, 2013

Society of Nuclear Medicine Celebrates 60th Annual Meeting

Meeting highlights nuclear medicine and molecular imaging advances from bench to bedside

April 11, 2013 — An estimated 5,000 nuclear medicine and molecular imaging professionals are expected to gather in June for the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to discuss the latest advances in radiotracers, imaging modalities, radionuclide therapies and quality.

The meeting will be held June 8-12 in Vancouver, British Columbia, Canada. This year’s meeting marks the 60th anniversary of the SNMMI Annual Meeting.

“Our first meeting was held in Seattle, Wash., in 1954, and was reported to have had 109 attendees who heard 13 scientific presentations and one panel discussion,” said Peter Herscovitch, M.D., chair of SNM’s Scientific Program Committee (SPC).  

Today, the SNMMI Annual Meeting offers education opportunities for physicians, technologists, pharmacists, physicists, scientists and laboratory professionals in the nuclear medicine and molecular imaging fields. More than 110 expert-led continuing education sessions will be held on topics including emerging PET radiotracers, dementia, neuroendocrine tumor imaging, novel targeted radiopharmaceutical therapies and hybrid imaging. Several other special courses will be held, including 11 categorical sessions, 22 self-assessment modules, a two-day CT case review workshop and a new Education Forum designed specifically for nuclear medicine program directors. The Annual Meeting will also feature a special session honoring Henry N. Wagner, Jr., M.D., nuclear medicine pioneer and visionary, who died last year.

SNMMI will again offer its Virtual Meeting for those who missed sessions of interest at the meeting or those unable to travel to Vancouver. The Virtual Meeting will include 70 of the most popular sessions, captured on video and available to view online or on a mobile device.

For more information: www.snmmi.org/am2013

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
Overlay Init